Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iradimed (IRMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Iradimed (IRMD) over the last 13 years, with Q3 2025 value amounting to $666083.0.

  • Iradimed's Share-based Compensation rose 573.35% to $666083.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 1905.25%. This contributed to the annual value of $2.5 million for FY2024, which is 1543.85% up from last year.
  • Per Iradimed's latest filing, its Share-based Compensation stood at $666083.0 for Q3 2025, which was up 573.35% from $730618.0 recorded in Q2 2025.
  • Over the past 5 years, Iradimed's Share-based Compensation peaked at $826064.0 during Q1 2025, and registered a low of $121003.0 during Q2 2022.
  • For the 5-year period, Iradimed's Share-based Compensation averaged around $515141.5, with its median value being $533748.0 (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first tumbled by 8653.4% in 2021, then skyrocketed by 36978.5% in 2023.
  • Quarter analysis of 5 years shows Iradimed's Share-based Compensation stood at $391784.0 in 2021, then rose by 8.88% to $426555.0 in 2022, then grew by 29.19% to $551064.0 in 2023, then rose by 19.19% to $656835.0 in 2024, then grew by 1.41% to $666083.0 in 2025.
  • Its Share-based Compensation stands at $666083.0 for Q3 2025, versus $730618.0 for Q2 2025 and $826064.0 for Q1 2025.